Aneurysmal subarachnoid hemorrhage remains one of the most devastating forms of stroke, carrying high rates of mortality and persistent disability. Clinicians have long sought medical therapies to prevent early rebleeding before definitive surgical or endovascular aneurysm repair occurs. The use of antifibrinolytic agents appeared promising in theoretical models; however, recent large randomized investigations demonstrated a notable absence of overall clinical benefit. The pivotal ULTRA trial specifically showed that early antifibrinolytic administration failed to improve functional status at six months. To understand whether heterogeneous subgroup responses masked potential benefits or harms, investigators performed a comprehensive post hoc evaluation. This investigation explored sex-specific trajectories and revealed critical insights regarding the administration of tranexamic acid in aSAH. The findings provide vital nuance for emergency physicians, neurologists, neurosurgeons, and intensive care specialists who manage acute neurovascular emergencies.

Investigating Sex-Specific Disparities in ULTRA Trial Data

The original ULTRA trial was a prospective, multicenter, randomized controlled open-label trial with blinded endpoint evaluation conducted across multiple high-volume stroke centers. Investigators assigned patients presenting with spontaneous subarachnoid hemorrhage to receive either ultra-early, short-term antifibrinolytic therapy alongside standard management or standard medical care alone. In this specific post hoc investigation, researchers restricted their analysis exclusively to eight hundred twelve participants with radiologically confirmed ruptured intracranial aneurysms. Among this cohort, females comprised seventy-one percent, reflecting the well-known epidemiological preponderance of cerebral aneurysms in women. Within the female group, two hundred eighty-six individuals received antifibrinolytic infusion, whereas one hundred nine of the two hundred thirty-five male patients received the active treatment regimen. The primary objective focused on testing whether biological sex modified the therapeutic relationship between intervention and long-term functional recovery.

Evaluating Functional Endpoints and Male Outcomes with Tranexamic Acid in aSAH

Researchers designated functional recovery at six months as the primary outcome, measured across the complete distribution of the modified Rankin Scale. Ordinal regression models adjusted for baseline prognostic factors demonstrated a statistically significant interaction between patient sex and treatment allocation. In female patients, receiving short-term antifibrinolytic therapy did not alter functional distribution or functional independence rates at six months. Conversely, male patients exposed to tranexamic acid in aSAH demonstrated a markedly unfavorable shift in disability scores. Specifically, treated males experienced an adjusted odds ratio of 1.94 for worse functional outcomes across the modified Rankin Scale compared to untreated counterparts. Secondary endpoints, including thirty-day all-cause mortality, six-month mortality, and predefined in-hospital complication rates, did not demonstrate statistically significant individual differences between the male cohorts. Nonetheless, the overall shift toward greater neurological impairment highlights an unexpected, sex-specific vulnerability to antifibrinolytic therapy.

Potential Pathophysiological Mechanisms Behind Male Vulnerability

The biological mechanisms driving worse neurological outcomes in males following antifibrinolytic therapy warrant careful examination. Ruptured cerebral aneurysms trigger complex pathophysiological cascades involving acute microvascular thrombosis, impaired cerebral autoregulation, and delayed cerebral ischemia. Antifibrinolytic agents inhibit plasminogen activation, which stabilizes early clot formation at the aneurysm rupture site but simultaneously promotes microthrombosis within distal cerebral capillaries. Furthermore, experimental data demonstrate substantial sex differences in baseline neurovascular inflammatory cascades and baseline fibrinolytic activity. Estrogen provides established neuroprotective effects on endothelial nitric oxide synthase expression, whereas testosterone can amplify platelet aggregation and enhance cerebral vasoconstrictive reactivity. Consequently, male patients may experience heightened microvascular thrombosis and worsened microcirculatory perfusion when exposed to antifibrinolytic agents during the acute phase of hemorrhage. This severe microvascular compromise could exacerbate secondary ischemic brain injury without necessarily manifesting as macroscopic vessel vasospasm.

Clinical Implications for Acute Neurocritical Care Management

These findings reinforce current international clinical neurovascular guidelines, which advise against the routine administration of systemic antifibrinolytic agents in acute subarachnoid hemorrhage. While clinicians historically considered short-course therapy as a temporary bridge to definitive securement, clinical trial evidence consistently demonstrates that preventing early rebleeding does not translate into improved functional survival. The observed detrimental effect among males adds a critical safety signal to existing literature. Clinicians should prioritize rapid transport to comprehensive stroke centers, immediate noninvasive vascular imaging, blood pressure control, and ultra-early aneurysm securement via endovascular coiling or surgical clipping. Relying on pharmacological stabilization risks worsening cerebral microcirculatory collapse, particularly in male patients. Therefore, clinical teams must exercise strict discipline and avoid routine antifibrinolytic protocols in emergency departments and intensive care units.

Future Directions and Individualized Hemorrhage Protocols

Modern stroke research increasingly emphasizes precision medicine, acknowledging that identical therapeutic interventions can yield divergent responses based on biological sex and clinical phenotype. While post hoc subgroup evaluations require cautious interpretation due to inherent statistical limitations, the significant interaction observed in the ULTRA trial demands further prospective scientific exploration. Future translational studies should investigate sex-specific biomarkers of coagulation, fibrinolysis, and endothelial dysfunction in acute neurovascular injury. Additionally, neurocritical care researchers must explore targeted neuroprotective strategies that mitigate microvascular thrombosis while preserving systemic hemostasis. Understanding how biological sex influences acute cerebral injury cascades will enable clinicians to design individualized, highly targeted interventions. Ultimately, optimizing outcomes in ruptured intracranial aneurysms requires aggressive early physiological stabilization, swift surgical intervention, and the deliberate avoidance of therapies associated with delayed neurovascular harm.

Frequently Asked Questions (FAQs)

What did the ULTRA trial post hoc analysis reveal regarding male patients?

The post hoc analysis revealed that male patients receiving ultra-early tranexamic acid experienced significantly worse six-month functional recovery compared to those receiving standard care alone. The analysis demonstrated an adjusted odds ratio of 1.94 for greater disability across the modified Rankin Scale, showing a clear sex-specific detrimental effect.

Did female patients experience similar adverse outcomes from tranexamic acid?

No, female patients did not demonstrate significant differences in six-month functional recovery or mortality when treated with tranexamic acid compared to standard care. However, because antifibrinolytic therapy also provided no clinical benefit or improvement in functional independence among females, routine clinical use remains unsupported across all patient populations.

Should clinicians ever administer tranexamic acid in acute subarachnoid hemorrhage?

Current clinical guidelines and robust trial evidence recommend against the routine use of tranexamic acid in acute aneurysmal subarachnoid hemorrhage. Clinicians should instead focus on rapid diagnostic confirmation, strict blood pressure management, and ultra-early definitive aneurysm securement through endovascular coiling or neurosurgical clipping at comprehensive neurovascular centers.

Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice, diagnosis, or treatment. Any clinical decisions should be made in consultation with a qualified healthcare provider. Refer to the latest local and national guidelines for clinical practice.

References

1. Koopmans RJ et al. Tranexamic acid after aneurysmal subarachnoid hemorrhage is associated with worse outcome in males: post hoc analysis of the ULTRA trial. J Neurol. 2026 Aug 19. doi: 10.1007/s00415-026-14037-z. PMID: 42616160.
2. Post R, Germans MR, Tjerkstra MA, et al. Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial. Lancet. 2021;397(10269):112-118.
3. Hoh BL, Ko NU, Amin-Hanjani S, et al. 2023 Guideline for the Management of Patients With Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2023;54(7):e314-e370.
4. Tjerkstra MA, Post R, Germans MR, et al. Ultra-Early and Short-Term Tranexamic Acid Treatment in Patients With Good- and Poor-Grade Aneurysmal Subarachnoid Hemorrhage. Neurology. 2024;102(12):e209169.